Plaintiff
5 cases as plaintiff.
Company overview. Incyte Genomics, Inc. was the Palo Alto, California–based name of the publicly traded genomics company (Nasdaq: INCY) from March 2000 to March 2003, when it was renamed Incyte Corporation. It was originally incorporated in 1991 as Incyte Pharmaceuticals, Inc. Incyte Genomics existed as a real operating company with products and customers, not a patent-holding shell. At the time of its tracked suits it reported roughly $194–220 million in annual revenue (2000–2001) and roughly 1,100 employees before restructuring cuts. Its successor, Incyte Corporation, is today a Wilmington, Delaware–headquartered biopharmaceutical company.
Products / operations. Incyte Genomics sold commercial gene-sequence and proteome databases (LifeSeq, ZooSeq, and the BioKnowledge Library) under subscription to pharmaceutical and biotech researchers, plus custom genomics services and, through subsidiary Synteni, Inc., microarray (GEM) technology for gene-expression analysis. It also licensed its gene, RNA-amplification, and microarray-fabrication patent portfolio. In late 2001 the company exited microarray manufacturing and refocused on drug discovery; by 2003 the renamed Incyte Corporation was transitioning to the therapeutics business it operates today.
Patent-litigation posture. With two tracked cases and zero as defendant, Incyte Genomics appears in the database purely as a plaintiff. This reflects real competitive patent enforcement by an operating company, not NPE activity: its suits asserted patents developed internally or exclusively licensed from Stanford and Layton Bioscience, and both were responses in broader two-way fights with industry rivals. Cases sit in the Northern and Southern Districts of California — no plaintiff-friendly Texas venue is involved.
Notable cases. In Incyte Genomics v. Affymetrix (N.D. Cal., filed 2000), Incyte asserted RNA-amplification patents (U.S. 5,716,785; 5,891,636) against Affymetrix's GeneChip business; the parties settled in December 2001 with cross-licenses and a $4.5 million payment to Incyte. In Incyte Genomics v. Invitrogen (S.D. Cal., filed Nov. 21, 2001), Incyte alleged infringement of 16 patents (gene clones, RNA amplification, and microarray fabrication) — filed the same day it answered Invitrogen's earlier Delaware suit; the case was dismissed by stipulation in February 2004.
Watchlist
Email-only, free, anonymous. We'll notify you when Incyte Genomics, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Incyte Genomics asserted sixteen patents, including U.S. Patent Nos. 5,807,522 and 6,110,426, which related to methods of fabricating microarrays of biological samples. Incyte sought injunctive relief, damages, treble damages for alleged willful infringement, fees, costs, and interest. The ultimate disposition of the case was not verified in the retrieved sources.
Incyte-initiated declaratory-judgment action relating to the Affymetrix patent litigation, resolved as part of the same December 21, 2001 global settlement as the Affymetrix v. Synteni/Incyte cases.
Incyte Genomics sued Affymetrix in N.D. Cal.; the case was settled on December 21, 2001 as part of the global Affymetrix–Incyte settlement. The narrative does not specify which patents were asserted in this case.
Incyte Genomics, Inc., as exclusive licensee of Stanford's patents, sued Gene Logic, Inc. for infringement in the Northern District of California. The case asserted U.S. 5,716,785, U.S. 5,891,636, and U.S. 6,023,659. It settled in January 2001, the lawsuits were dismissed, and Gene Logic received a non-exclusive license.
Incyte Genomics, Inc. sued Affymetrix, Inc. in the Northern District of California, asserting U.S. 5,716,785 and U.S. 5,891,636; Affymetrix counterasserted U.S. 5,871,928 and U.S. 6,040,193. The related N.D. Cal. cases settled on December 21, 2001, with all claims, defenses, and counterclaims dismissed with prejudice and cross licenses granted.